How Anxiety and Depression Inflate the RSIMarch 20, 2018
Voice Problems, Negative Manometry, and Negative Esophageal pH TestApril 30, 2018
Houston, TX, 04/24/18: Respiratory Technology Corporation (Restech) announced today the asset acquisition of Mederi Therapeutics Inc. In response to the increasing need for therapeutic options to address the growing conditions of reflux disease and gastric disease, Restech welcomes the addition Stretta® and Secca® technology to their product portfolio. These new innovative product lines complement Restech’s existing diagnostic devices with therapeutic solutions, provide additional clinical pathways, and broaden Restech’s global distribution network.
“This acquisition provides a unique opportunity to expand our reach across the clinical spectrum,” says Debra Krahel, CEO, “With the addition of Mederi’s technology and market penetration, and Restech’s established space in the reflux market, these complementary products will address gaps in the clinical continuum.”
Stretta (for GERD) and Secca (for bowel incontinence) both utilize low-power radiofrequency (RF) energy to remodel the sphincter muscle at either end of the digestive tract, thereby improving function, providing significant symptom relief, and dramatic improvement in quality-of-life.
Stretta and Secca will be marketed through Mederi RF LLC, a wholly owned subsidiary of Restech. Announcements will be made in the coming days detailing the key staff who will join Restech’s management team.
As the only nonsurgical procedure for the treatment of reflux disease, Stretta is minimally invasive and has provided consistent patient results for more than a decade. A 2017 meta-analysis published in Surgical Endoscopy concluded “The Stretta procedure significantly improves subjective and objective clinical endpoints.”
“Stretta reduces esophageal acid exposure, decreases the frequency of transient lower esophageal relaxation, increases patient satisfaction, decreases medication use, and improves quality of life. As such, this procedure remains a valuable nonsurgical treatment option in the management of gastroesophageal reflux disease.” (Gastroenterology Research and Practice, 2013)
Interested in learning more about Restech’s reflux diagnostic and therapeutic products? Click below to request a demo.
Restech is a leader in engineering world class medical technologies that provide comfortable, reliable solutions to assist physicians in the diagnosis of reflux related health problems quickly and reliably. The innovative engineering team at Restech is led by professionals with over two decades experience each in medical device development. Together, the Restech staff hold over 30 patents in the areas of sensor technology, data recording and monitoring systems, and other medical devices.